Trial Profile
Three Seasonal Palivizumab Doses Over Four Seasons as RSV Prophylaxis for Moderate Risk Infants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 18 Aug 2015 New trial record